ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "COVID-19"

  • Abstract Number: 1144 • ACR Convergence 2020

    Concerns and Behaviors of Patients with Common Autoimmune Rheumatic Diseases in the United States Early in the COVID-19 Pandemic

    Michael George1, Shilpa Venkatachalam2, Shubhasree Banerjee1, Joshua Baker1, Peter Merkel1, David Curtis3, Kelly Gavigan4, Maria (Maio) Danila5, Jeffrey R Curtis6 and William Nowell7, 1University of Pennsylvania, Philadelphia, PA, 2Global Healthy Living Foundation, Upper Nyack, 3Global Healthy Living Foundation, New York City, 4Global Healthy Living Foundation, Upper Nyack, NY, 5University of Alabama at Birmingham (UAB), Birmingham, AL, 6Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 7Global Healthy Living Foundation, New York City, NY

    Background/Purpose: Patients with autoimmune rheumatic diseases may be particularly concerned about COVID-19. We aimed to assess concerns and associated health behaviors of patients with autoimmune…
  • Abstract Number: 1584 • ACR Convergence 2020

    Telemedicine Visits During COVID-19 Improved Clinic Show Rates

    Reem Alkilany1 and Raymond Hong2, 1MetroHealth medical center, lakewood, OH, 2Metrohealth Medical center, Richfield, OH

    Background/Purpose: The COVID-19 pandemic has tremendously affected the healthcare sector. State of Ohio officials recommended to hold in-person outpatient visits and elective procedures to limit…
  • Abstract Number: 0011 • ACR Convergence 2020

    Patients Receiving Cytokine Inhibitors Have Low Prevalence of SARS-CoV-2 Infection

    David Simon1, Koray Tascilar1, Gerhard Krönke2, Arnd Kleyer1, Mario Zaiss3, Franz Heppt4, Christine Meder4, Raja Atreya5, Entcho Klenske5, Peter Dietrich5, Abdullah Abdullah5, Thorsten Kliem5, Giulia Corte6, Harriet Morf3, Moritz Leppkes5, Andreas Kremer5, Andreas Ramming3, Milena Pachowsky7, Florian Schuch8, Monika Ronneberger9, Stefan Kleinert10, Clara Maier11, Axel Hueber12, Karin Manger13, Bernhard Manger3, Carola Berking4, Matthias Tenbusch11, Klaus Überla11, Michael Sticherling3, Markus Neurath5 and Georg Schett14, 1Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, 2Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Georgia, 3Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, 4Department of Dermatology, FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, 5Department of Internal Medicine 1, FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, 6Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Gibraltar, 7Department of Orthopedic and Trauma Surgery, FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, 8Rheumatology Clinical Practice Erlangen, Erlangen, Ghana, 9Rheumatology Clinical Practice Erlangen, Erlangen, Germany, 10Rheumatology-Nephrology Practice, Erlangen, Germany, 11Institute of Clinical and Molecular Virology, FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, 12Sozialstiftung Bamberg, Sektion Rheumatologie, Bamberg, Germany, 13Rheumatology Practice Bamberg, Bamberg, Germany, 14Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany

    Background/Purpose: Therapeutic interventions for Immune-mediated inflammatory diseases (IMIDs) target cytokines, such as TNF-a, IL-6, IL-17 and IL-23, which are involved in the physiological and pathological…
  • Abstract Number: 0413 • ACR Convergence 2020

    Coronavirus Infection and Vasculitis: Identifying Associations Mining the Biomedical Literature

    Alicia Rodriguez Pla1 and Rodrigo Cartin-Ceba2, 1Rheumatology. Mayo Clinic Arizona, Scottsdale, 2Pulmonary. Mayo Clinic Arizona, Scottsdale, AZ

    Background/Purpose: Based on recent publications suggesting an association between COVID-19 and vascular inflammation, our aim was to explore new associations between coronavirus infections and vasculitis…
  • Abstract Number: 0545 • ACR Convergence 2020

    The Use of Tocilizumab and Tofacitinib in Patients with Resolved Hepatitis B Infection: A Case Series

    Naomi Serling-Boyd1, Amir Mohareb2, Arthur Kim2, Emily Hyle2 and Zachary Wallace3, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Boston, 3Massachusetts General Hospital, Newton, MA

    Background/Purpose: The use of immunosuppressive medications in patients with a history of hepatitis B virus (HBV) infection is associated with an increased risk of HBV…
  • Abstract Number: 0629 • ACR Convergence 2020

    COVID-19 Among Patients with Immune-mediated Inflammatory Diseases: A Descriptive Study

    Jesús Loarce-Martos1, Antía García-Fernández1, Fernando López-Gutiérrez1, Veronica Garcia2, Laura Calvo-Sanz1, Ivan Del Bosque-Granero2, Cristina Pijoan-Moratalla1, Lourdes Villalobos-Sánchez3, Boris Blanco-Cáceres1, Javier Bachiller-Corral1 and Mónica Vázquez1, 1Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, 2Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, 3Rheumatology, Hospital Universitario Ramón y Cajal, Madrid

    Background/Purpose: Patients with immune-mediated inflammatory diseases (IMID) have a higher risk of infections related to their disease, comorbidities or immunosuppressive treatments, but recent studies addressing…
  • Abstract Number: 1267 • ACR Convergence 2020

    Perceived Stress During the COVID-19 Pandemic Independently Associates with Worse Patient-Reported Outcomes in Systemic Lupus Erythematosus (SLE)

    Sarah Patterson1, Laura Trupin2, Kimberly DeQuattro1, Cristina Lanata1, Maria Dall'Era3, Jinoos Yazdany2 and Patricia Katz2, 1UCSF, San Francisco, CA, 2University of California, San Francisco, San Francisco, CA, 3Division of Rheumatology, University of California, San Francisco, CA

    Background/Purpose: Causes and risk factors for variations in SLE disease activity and symptom severity are incompletely understood. Prior studies suggest a link between stressful life…
  • Abstract Number: 1585 • ACR Convergence 2020

    Lessons Learned Through Rapid Quality Improvement for Telehealth Implementation in an Academic Rheumatology Practice During the COVID-19 Pandemic

    Julie Thomas1, Dorota Lebiedz-Odrobina1, Kyle Register1, Francesca Ferrara1, Danielle Barlow1, Alicia Riddle1 and Karla Miller2, 1University of Utah, Salt Lake City, UT, 2Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT

    Background/Purpose: The COVID-19 pandemic created an urgent need for access to care while preserving patient safety through social distancing. Prior to the pandemic, patients were…
  • « Previous Page
  • 1
  • …
  • 38
  • 39
  • 40
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology